ASRS 2024: Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography

News
Video

Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.

Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.

Video Transcript:

Editor's note: The below transcript has been lightly edited for clarity.

Sruthi Arepalli, MD:

Hi, everyone. I'm Sruthi Arepalli, an assistant professor at Emory University at the ASRS. This year, I had the pleasure of presenting our research, which looked at retinal vascular changes in patients with Alzheimer's disease. And essentially what we were able to find is that patients with Alzheimer's disease tend to have more complexity to their architecture of their blood vessels. And this was particularly prominent when we looked at their arteries alone, and compared them to patients who are considered cognitively normal.

We also wanted to know if these features correlated with their cerebrospinal fluid, which is the gold standard for diagnosis for Alzheimer's disease. And we saw that the increased level of complexity or entropy of their blood vessels was correlated to certain proteins that become elevated in Alzheimer's disease. And we also found that using these 2 markers in conjunction with each other are the best to discriminate out patients with Alzheimer's as compared to those who are cognitively normal.

The usage of AI is really incredible because it can help us select out patients, particularly Alzheimer's patients that are earlier on in their disease process. One of the devastating things about Alzheimer's disease is that these patients get cognitive deficits that occur very late in their disease. And so if we can find a biomarker like the retina to target earlier, we may be able to find their disease earlier as well.

So our data was based on a study that was already ongoing through the Emory Center, it was called the Emory Brain Health Study. And so what we had done was we had placed fundus imaging equipment within the neurology department that was already seeing these patients to get their baseline images. And then we retrospectively went back and looked at them, because ours was just sort of a snapshot image of a patient who had come in for a visit. And so all together, we're able to show that there's increased complexity, but we were not able to longitudinally track them in this portion of the study.

You know, we're still in the early processes of delineating what features to look out for for defining early onset Alzheimer's disease, but it is promising that we have some potential tips. I think we still have to fine tune a lot of the exclusivity criteria and what to filter out when we look at these patients but it's an exciting time.

Recent Videos
3 experts are featured in this series.
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.